We found that five anti-EBV antibodies (BLLF3-IgA, BLRF2-IgA, BLRF2-IgG, BDLF1-IgA, BDLF1-IgG) combined with the the clinical biomarker EBNA1-IgA could be used to diagnose NPC accurately. Here, CD79A is linked to nasopharyngeal carcinoma.